Trump Orders Faster Review of Psychedelic Therapies for Serious Mental Illness

President Donald Trump on Saturday ordered the federal government to accelerate research and regulatory review of psychedelic drugs for serious mental illness, with ibogaine emerging as the clearest early focus. The order says the administration will prioritize certain psychedelic candidates at the FDA, create a pathway for eligible patients to seek access under the federal Right to Try law, and direct at least $50 million in existing Health and Human Services funds toward work with states on these treatments.

Addressing Mental Health Crises

The White House framed the move around suicide, treatment-resistant psychiatric illness and veterans’ care. In the order, Trump said more than 14 million U.S. adults live with serious mental illness and that veteran suicide has remained above 6,000 cases a year for more than two decades. The administration argued that existing medications and standard psychiatric care do not produce lasting improvement for some of the sickest patients, creating pressure for new approaches.

Psychedelics and Federal Law

The policy does not remove psychedelics from Schedule I, the federal category reserved for drugs deemed to have high abuse potential and no currently accepted medical use. That means substances such as psilocybin, LSD and ibogaine remain illegal outside tightly controlled research and other limited channels, even as the administration signals greater interest in their therapeutic potential. The order instead focuses on speeding review of specific products and easing some research and access bottlenecks.

Beneficiaries of the Order

The immediate winners are researchers, veterans’ advocates and states trying to build treatment programs around experimental psychedelic medicine. The order instructs HHS, the FDA and the Department of Veterans Affairs to expand clinical-trial participation, data sharing and real-world evidence collection, particularly for drugs that have already received FDA Breakthrough Therapy designation. It also tells the attorney general, working with HHS, to move quickly on rescheduling any specific Schedule I-based product that completes Phase 3 trials and later wins approval.

Focus on Ibogaine

Ibogaine sits at the center of that push. The plant-derived psychoactive compound has drawn attention from some veterans and addiction-treatment advocates because of small studies and anecdotal reports suggesting possible benefits for post-traumatic stress disorder, traumatic brain injury and substance-use disorders. At the same time, major safety concerns remain: ibogaine has been linked to dangerous cardiac effects, and AP reported that U.S. human trials are only now being set to begin.

Impact on Drug Industry

For the drug industry and mental-health field, the order marks a rare federal opening for a class of substances long pushed to the edge of mainstream medicine. It could encourage biotech companies, academic medical centers and state policymakers to invest more heavily in psychedelic programs, especially if FDA review times shorten and federal agencies become more willing to coordinate on evidence gathering. Even without immediate approvals, the order gives political legitimacy to an area that only recently sat far outside conventional drug policy.

Broader Policy Implications

The wider policy signal is just as important. Trump’s move suggests the administration is willing to separate research access from full legalization, using regulatory flexibility rather than sweeping drug-law reform. That approach may broaden bipartisan support, particularly where the issue is tied to veterans and addiction, but it also leaves the central tension unresolved: advocates want faster access, while regulators still need convincing proof on safety, dosing and durability of benefit.

Challenges Ahead

The next test is whether the agencies can translate the order into actual trials, clearer FDA pathways and usable patient access without outrunning the evidence. Questions also remain over how much of the $50 million can be deployed quickly, which states will qualify for partnerships, and whether ibogaine or any other psychedelic product can generate the Phase 3 data needed for approval and later rescheduling. Reports around the signing tied the effort partly to advocacy from Joe Rogan and other backers, but the harder part starts now: turning political momentum into credible clinical results.